MESA LABORATORIES INC (MLAB) is the issuer for which BlackRock, Inc. reported beneficial ownership of 443,662 common shares, or 7.9%, as of September 30, 2026. BlackRock reported sole voting power over 436,324 shares and sole dispositive power over 443,662 shares; shared voting and dispositive power were each 0. The reported position reflects securities attributed to certain BlackRock business units and excludes securities of business units whose beneficial ownership is disaggregated. Various persons have rights to receive or direct dividends or sale proceeds, but no one person's interest exceeds 5% of outstanding common shares.
Mesa Laboratories, Inc. (MLAB) approved a restructuring and savings plan expected to reduce annualized operating costs by approximately $9.3 million. It plans to reinvest approximately $4.3 million in growth and infrastructure, leaving an expected net annualized reduction of approximately $5.0 million. Savings are expected to be fully reflected by the end of fiscal year 2028.
The plan includes eliminating approximately 40 positions, or approximately 6% of its employee base, mainly in Clinical Genomics and corporate functions; reducing the San Diego facility footprint and third-party spending; and exiting its Hamburg facility when its lease expires in February 2027. Estimated pre-tax charges are $2.6 million to $3.4 million, and cash expenditures are $2.9 million to $3.7 million. Charges are expected primarily in the second half of fiscal year 2027, with substantially all cash expenditures over the next 12 months. The program is expected to be substantially complete by the end of fiscal year 2027, except for certain international exits expected in the first half of fiscal year 2028, subject to protected notice periods. Estimates for certain international operations remain subject to local employee consultation processes. Mesa expects lower Clinical Genomics revenue but higher profitability and gross profit percentage.
Mesa Laboratories Inc. is the issuer of shares for which Wasatch Advisors reported beneficial ownership of 387,129 common shares, or 6.9% of the class. Wasatch Advisors reported sole voting power over 261,101 shares and sole dispositive power over 387,129 shares, with no shared voting or dispositive power. The schedule was signed by Mike Yeates, listed with the title CEO.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Capone Mark Christopher reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Mark Christopher Capone received a grant of 2,423 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of the company’s common stock and is scheduled to vest on September 9, 2027. Following this award, he holds 2,423 RSUs directly. No Rule 10b5-1 trading plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Ladiwala Shiraz Shabanali reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Shiraz Shabanali Ladiwala received a grant of 2,510 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and vests on September 9, 2027. Following this grant, Ladiwala holds 2,510 RSUs directly, and no Rule 10b5-1 trading plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Alltoft Jennifer Sadie reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Jennifer Sadie Alltoft received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2009. Each RSU represents a contingent right to receive one share of common stock and vests on September 9, 2027. After this award, she holds 1,774 RSUs directly, and no Rule 10b5-1 plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Hall Shannon reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Shannon Hall received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and is scheduled to vest on September 9, 2027, resulting in direct ownership of 1,774 RSUs following the award.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Sullivan John James reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director John James Sullivan received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and is scheduled to vest on September 9, 2027, resulting in direct holdings of 1,774 RSUs.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Tripeny R Tony reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director R. Tony Tripeny received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of Mesa Laboratories common stock and vests on September 9, 2027. Following this award, the reporting person holds 1,774 RSUs directly. No transactions were made under a Rule 10b5-1 trading plan.
MESA LABORATORIES, INC. (MLAB) reported the results of its September 8, 2026 annual meeting of shareholders. Holders of 5,595,869 common shares were entitled to vote, and 4,872,692 shares were represented in person or by proxy.
All seven director nominees — John Sullivan, Siddhartha Kadia, Shiraz Ladiwala, Jennifer “Jenny” Alltoft, Mark Capone, Shannon Hall, and R. Tony Tripeny — were elected to one-year terms, each receiving over 4.35 million votes in favor, with broker non-votes recorded. Shareholders also approved the ratification of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, with 4,814,383 votes for. On a non-binding advisory basis, shareholders approved the compensation of the named executive officers, with 4,317,389 votes for and 136,782 against.